Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting

D. Generali, F. Montemurro, R. Bordonaro, A. Mafodda, S. Romito, A. Michelotti, P. Piovano, M.T. Ionta, C. Bighin, D. Sartori, A. Frassoldati, M.E. Cazzaniga, F. Riccardi, F. Testore, P. Vici, C.A. Barone, A. Schirone, F. Piacentini, F. Nolé, A. MolinoL. Latini, E.L. Simoncini, F. Roila, F. Cognetti, F. Nuzzo, J. Foglietta, A.M. Minisini, F. Goffredo, G. Portera, G. Ascione, G. Mariani

Research output: Contribution to journalArticle

Abstract

Background. The BALLET study was an open-label, multicenter, expanded access study designed to allow treatment with everolimus plus exemestane in postmenopausal women with hormone receptor-positive metastatic breast cancer progressed following prior endocrine therapy. A post hoc analysis to evaluate if previous chemotherapy in the metastatic setting affects the safety profile of the combination regimen of everolimus and exemestane was conducted on the Italian subset, as it represented the major part of the patients enrolled (54%). Patients and Methods. One thousand one hundred and fiftyone Italian patients were included in the present post hoc analysis, which focused on two sets of patients: patients who never received chemotherapy in the metastatic setting (36.1%) and patients who received at least one chemotherapy treatment in the metastatic setting (63.9%). Results. One thousand one hundred and sixteen patients (97.0%) prematurely discontinued the study drug, and the main reasons reported were disease progression (39.1%), local reimbursement of everolimus (31.1%), and adverse events (AEs) (16.1%). The median duration of study treatment exposure was 139.5 days for exemestane and 135.0 days for everolimus. At least one AE was experienced by 92.5% of patients. The incidence of everolimus-related AEs was higher (83.9%) when compared with those that occurred with exemestane (29.1%), and the most commonly reported everolimus-related AE was stomatitis (51.3%). However, no significant difference in terms of safety related to the combination occurred between patients without and with chemotherapy in the metastatic setting. Conclusion. Real-life data of the Italian patients BALLET-related cohort were an adequate setting to state that previous chemotherapy did not affect the safety profile of the combination regimen of everolimus and exemestane. © AlphaMed Press 2017.
Original languageEnglish
Pages (from-to)648-654
Number of pages7
JournalOncologist
Volume22
Issue number6
DOIs
Publication statusPublished - 2017

Keywords

  • Advanced breast cancer
  • Everolimus
  • Hormone-receptor positive
  • Real life
  • Safety

Fingerprint Dive into the research topics of 'Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting'. Together they form a unique fingerprint.

Cite this